Evolution: ANP32B, or not to be, that is the question for influenza virus
Every year, the influenza A virus causes flu epidemics around the world, and is also responsible for deadly pandemics like that of 1918. Like most viruses, it must hijack host cells to express its genes, replicate its genome, and produce new virions to infect more cells. Diverse populations of influenza A viruses circulate in birds, their natural reservoir, before emerging in humans and other mammals. As the bird viruses adapt to non-avian species, they face two major barriers: entering the cells of their new hosts, and being able to use their polymerase complex to replicate their genomes (Te Velthuis and Fodor, 2016; Long et al., 2019a). Entry into cells is controlled by receptors that the viruses must bind to, with different species expressing different variants of the receptors. However, the mechanism that blocks the activity of the viral polymerase in a new host, thus preventing the virus from replicating, is less well understood. Looking into the ways that influenza A virus infects new species, and how the hosts fight back, offers a glimpse into complex evolutionary processes in action.
The influenza polymerase is a complex formed of three proteins including one called PB2 (Te Velthuis and Fodor, 2016). Avian-style polymerases work well in bird cells, but poorly in humans. This species-specific restriction is due to the amino acid at position 627 in the PB2 subunit, which is a glutamate in birds and a lysine in humans (Almond, 1977; Subbarao et al., 1993). Changing this glutamate to lysine in an avian polymerase is sufficient to make it active in human cells, but the reasons for this were unclear.
The viral polymerase must recruit proteins from the host in order to transcribe and replicate the viral genome. In 2016, Wendy Barclay of Imperial College and colleagues finally identified ANP32A, the long-sought host co-factor that controls species specificity (Long et al., 2016). There are up to four members of the ANP32 family in vertebrates (A, B, C, and E), all of which have a whip-like shape (Figure 1). Rigorous biochemistry showed that the ANP32 proteins were key co-factors of the viral polymerase in human cells, with ANP32A and ANP32B having redundant roles (Sugiyama et al., 2015). However, just one member of the family in chickens – ANP32A – was able to stimulate avian polymerases; expressing chicken ANP32A in human cells rescued activity of the viral polymerases in an otherwise inhospitable species.
However, it was not that human cells lacked ANP32A; rather, a duplication and insertion in chicken ANP32A added a unique exon to the gene. The insertion was common to almost all ANP32A proteins across birds and it was sufficient to confer activity to polymerases of avian origin. Subsequent studies began to dissect the activity of ANP32A and identified key features of this insert. In particular, they showed that, in birds, ANP32A is differentially spliced at the insert, creating ANP32A variants with different abilities to support polymerase function (Baker et al., 2018; Domingues and Hale, 2017). Thus, multiple lines of evidence converged on the importance of ANP32 proteins and their potential role in the evolution of influenza viruses. Now, in eLife, Barclay and colleagues at Imperial College, Edinburgh University, St George's in London and the Pirbright Institute – including Jason Long as first author – report, alongside a paper by Xiaojun Wang and colleagues in the Journal of Virology, that ANP32 proteins may have an even more intriguing evolutionary history (Long et al., 2019b; Zhang et al., 2019).
First, the experiments confirmed that ANP32A and ANP32B have a redundant role in helping the influenza virus to replicate in human cells. The double-knockout of ANP32A and ANP32B almost completely eliminated polymerase activity and virus replication, but simply deleting ANP32A had no effect (Long et al., 2019b; Zhang et al., 2019). HoweverIn contrast, removing only ANP32A in chickens was sufficient to stop the viral polymerase from working (Long et al., 2019b). Taken together, these results imply that both ANP32A and ANP32B support infection in humans, but only ANP32A performs this role in chickens, with ANP32B being unable to help the polymerase. Finally, neither human nor chicken ANP32Es played a major role during viral replication.
An in-depth investigation of ANP32B in chicken revealed that everything was not as it seemed. Evolutionary analyses showed that avian ANP32B forms a distinct group, and may actually be more closely related to ANP32C genes (and perhaps should be referred to as such) (Figure 1; Long et al., 2019b). Birds lost or never possessed the ANP32B version found in mammals, while the ANP32C gene that is closely related to avian ANP32B emerged in placental mammals as a non-functional pseudogene. Both Long et al. and Zhang et al. exploited their knockout cells to show that only two amino acid changes in chicken ANP32B eliminate its ability to support the viral polymerase (Figure 1). Avian ANP32A has asparagine and aspartate at residues 129 and 130, whereas avian ANP32B has isoleucine and asparagine at the same sites. These differences control the ability of the protein to interact with and promote the activity of the viral polymerase. Human ANP32A and ANP32B both have asparagine and aspartate at these sites, explaining why either protein supports the activity of the viral polymerase. These studies provide compelling evidence that subtle changes in ANP32 proteins can have large impacts on how viruses can exploit these proteins to replicate.
It is still unclear which evolutionary forces drove the duplication and subsequent diversification of the ANP32 loci, while also fixing the insertion in chicken ANP32A. How ANP32 proteins support the activity of the influenza polymerase also remains to be elucidated. In addition, it is likely that selective pressures on ANP32 proteins were not unique to birds. Mouse ANP32A, for example, only marginally supports polymerase activity (Zhang et al., 2019). In this species, ANP32A has asparagine and alanine at residues 129 and 130, a variation that the current studies would predict to be non-functional for the influenza virus. Instead, the mouse variant of ANP32B that has serine and aspartic acid at these sites is likely the dominant form which supports infection. It is curious that similar changes in ANP32A arise in pangolins, a species whose evolution is very distant from rodents and which has no obvious history with influenza virus. "For who would bear the whips of scorn and time", cries out Hamlet in the eponymous play. And indeed, the whip-like ANP32 proteins bear the telltale signs of mutation and diversification that suggest a long history of viruses exploiting these proteins.
References
-
Host and viral determinants of influenza A virus species specificityNature Reviews Microbiology 17:67–81.https://doi.org/10.1038/s41579-018-0115-z
-
A single amino acid in the PB2 gene of influenza A virus is a determinant of host rangeJournal of Virology 67:1761–1764.
-
Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesisNature Reviews Microbiology 14:479–493.https://doi.org/10.1038/nrmicro.2016.87
Article and author information
Author details
Publication history
- Version of Record published: June 10, 2019 (version 1)
Copyright
© 2019, Baker and Mehle
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,367
- views
-
- 180
- downloads
-
- 8
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Microbiology and Infectious Disease
In the Firmicutes phylum, GpsB is a membrane associated protein that coordinates peptidoglycan synthesis with cell growth and division. Although GpsB has been studied in several bacteria, the structure, function, and interactome of Staphylococcus aureus GpsB is largely uncharacterized. To address this knowledge gap, we solved the crystal structure of the N-terminal domain of S. aureus GpsB, which adopts an atypical, asymmetric dimer, and demonstrates major conformational flexibility that can be mapped to a hinge region formed by a three-residue insertion exclusive to Staphylococci. When this three-residue insertion is excised, its thermal stability increases, and the mutant no longer produces a previously reported lethal phenotype when overexpressed in Bacillus subtilis. In S. aureus, we show that these hinge mutants are less functional and speculate that the conformational flexibility imparted by the hinge region may serve as a dynamic switch to finetune the function of the GpsB complex and/or to promote interaction with its various partners. Furthermore, we provide the first biochemical, biophysical, and crystallographic evidence that the N-terminal domain of GpsB binds not only PBP4, but also FtsZ, through a conserved recognition motif located on their C-termini, thus coupling peptidoglycan synthesis to cell division. Taken together, the unique structure of S. aureus GpsB and its direct interaction with FtsZ/PBP4 provide deeper insight into the central role of GpsB in S. aureus cell division.
-
- Microbiology and Infectious Disease
Mechanisms by which Mycobacterium tuberculosis (Mtb) evades pathogen recognition receptor activation during infection may offer insights for the development of improved tuberculosis (TB) vaccines. Whilst Mtb elicits NOD-2 activation through host recognition of its peptidoglycan-derived muramyl dipeptide (MDP), it masks the endogenous NOD-1 ligand through amidation of glutamate at the second position in peptidoglycan side-chains. As the current BCG vaccine is derived from pathogenic mycobacteria, a similar situation prevails. To alleviate this masking ability and to potentially improve efficacy of the BCG vaccine, we used CRISPRi to inhibit expression of the essential enzyme pair, MurT-GatD, implicated in amidation of peptidoglycan side-chains. We demonstrate that depletion of these enzymes results in reduced growth, cell wall defects, increased susceptibility to antibiotics, altered spatial localization of new peptidoglycan and increased NOD-1 expression in macrophages. In cell culture experiments, training of a human monocyte cell line with this recombinant BCG yielded improved control of Mtb growth. In the murine model of TB infection, we demonstrate that depletion of MurT-GatD in BCG, which is expected to unmask the D-glutamate diaminopimelate (iE-DAP) NOD-1 ligand, yields superior prevention of TB disease compared to the standard BCG vaccine. In vitro and in vivo experiments in this study demonstrate the feasibility of gene regulation platforms such as CRISPRi to alter antigen presentation in BCG in a bespoke manner that tunes immunity towards more effective protection against TB disease.